Enhancing Recovery after Radical Prostatectomy
At Levee Medical®, we are committed to designing solutions that aim to reduce complications associated with surgical treatment.
One in 8 men will develop prostate cancer*
Patients often choose surgery to treat prostate cancer
In most cases, surgery enables complete and immediate removal of cancer.
Urinary incontinence after prostatectomy remains a debilitating problem
It is the most feared complication following surgery for prostate cancer.
Life after prostatectomy deserves to be brillant
Our goal is to minimize incontinence so that patients can turn the page after prostate cancer surgery.
Introducing
Voro® Urologic Scaffold
The first and only bioresorbable device designed to address urinary incontinence in radical prostatectomy patients
Team
Bruce Choi
Founder, Director, CTO & Chairman
Adam Irving
CEO & Director
Kevin Hopkins
Vice President, Quality
Karen Cornett
Vice President, Clinical Affairs
Sean Collins
Vice President, Market Development
Gary McCord
Director
Peter Mulrooney
Director
Mike McKellar
Corporate Controller
Jeffrey Dann, M.D.
Duke Herrell, M.D.
Michael Ferrandino, M.D.
Melissa R Kaufman, M.D., PhD, FACS
Jeffrey Gahan, M.D.
Lee Ponsky, M.D.
News
Levee Medical Secures $4.3M Strategic Investment to Accelerate Clinical Development of the Voro Urologic Scaffold, Designed to Improve Robotic Prostatectomy Outcomes
Milestone Achieved as Company Announces Successful Enrollment of First Patients in its First-in-Human (FIH) Study
DURHAM, NC – Sept. 6, 2023 – Levee Medical, a clinical-stage medical device company designing solutions to improve surgical outcomes following prostate cancer, announced today it has raised a total of $4.3 million in oversubscribed funds. Additionally, Levee Medical successfully treated the first study participants in its first-in-human (FIH) study, demonstrating initial safety data for the Voro Urologic Scaffold.
Levee Medical™ Announces the Closing of $6.6m Series A Financing
Company to Accelerate Development of Novel Urologic Device Designed to Improve Recovery Outcomes Post-Prostatectomy
Durham, NC – August 23, 2022 – Levee Medical, a medical device company designing solutions to improve surgical outcomes following prostate cancer, announced today it has closed an initial oversubscribed series A financing round, raising a total of $6.6 million. The funds will be used to advance product development, scale infrastructure, and expand the team to support the development of the company’s Voro Urologic Scaffold, a bioresorbable post-prostatectomy implant.